

EMLc

Codes ATC: M04AA01

|                              |                                                                                                |                  |
|------------------------------|------------------------------------------------------------------------------------------------|------------------|
| Indication                   | Tumeur lysis syndrome                                                                          | Code ICD11: 5C70 |
| INN                          | Allopurinol                                                                                    |                  |
| Type de médicament           | Chemical agent                                                                                 |                  |
| Type de liste                | Liste complémentaire (EML) (EMLc)                                                              |                  |
| Formulations                 | Oral > Solid: 100 mg (EMLc) ; 300 mg (EMLc)                                                    |                  |
| Historique des statuts LME   | Ajouté pour la première fois en 2007 (TRS 950)                                                 |                  |
| Sexe                         | Tous                                                                                           |                  |
| Âge                          | Enfants (1 mois - 12 ans)                                                                      |                  |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique                                            |                  |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a> ↗ |                  |

Balises

Cancer supportive care

Wikipédia

[Allopurinol](#) ↗

DrugBank

[Allopurinol](#) ↗

## Résumé des preuves et recommandation du comité d'experts

Allopurinol was included on the complementary list of the first EMLc in 2007. The EMLc Subcommittee considered that allopurinol was necessary for management of children within oncology practice and that it should be included in cytotoxics and adjuvant medicines section of the EMLc for this indication.

